Titan Biotech Approves 1:4 Bonus Issue Subject To Shareholder Approval

Board approved 1:4 bonus issue of 1,03,29,625 shares and authorised capital increase to Rs 10.4Cr, subject to shareholder approval. Second capital restructuring within six months after the share split; bonus will be funded from reserves and/or securities premium. No cash is raised; record date is pending and bonus credit is targeted by November 3, 2026, subject to approvals.